Please ensure Javascript is enabled for purposes of website accessibility

Here's Why MacroGenics Stock Is Skyrocketing 171% Today

By Todd Campbell - May 6, 2020 at 1:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company could receive an FDA go-ahead on its lead drug candidate as soon as this year.

What happened

After MacroGenics (MGNX 3.65%) updated investors on its clinical-stage drug pipeline and current financial position, its shares are soaring 171% as of 12:45 am EDT Wednesday.

So what

MacroGenics' lead drug candidate is margetuximab, an optimized formulation of the top-selling breast cancer drug Herceptin. After the market's closing bell on Tuesday, the biotech company's management said it remains on track to report final overall survival (OS) data for the phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer this year. If the data is solid, MacroGenics believes it could get a Food and Drug Administration decision as soon as December 2020.

A rocket launching into the sky.

Image source: Getty Images.

Last year, the company announced that in a late-stage study, margetuximab produced progression-free survival (PFS) of 5.8 months, outperforming a 4.9-month PFS for Herceptin. 

MacroGenics also said that at the American Society of Clinical Oncology annual meeting this month, it will deliver an oral presentation from its ongoing phase 1 study of MGD013, for advanced solid-tumor patients.

Furthermore, the company offered up a bullish take on its cash runway. It believes the $170.8 million in cash and equivalents on its balance sheet can last it into 2022. 

Now what

Overall survival is the gold standard for proving the efficacy of drugs, so a positive readout later this year could ensure it secures market share as an alternative to Herceptin, a blockbuster medication. If the OS data isn't better than Herceptin, margetuximab could still secure an approval on PFS results. But that will depend a lot on the view of the FDA's Oncologic Drugs Advisory Committee, which is meeting in the second half of 2020 to discuss margetuximab's merits. 

The fact margetuximab isn't MacroGenics only intriguing drug in development is encouraging, too, so risk-tolerant investors able to withstand an FDA disappointment may want to consider picking up shares, especially if the advisory committee recommends the FDA give margetuximab a green light.

 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MacroGenics, Inc. Stock Quote
MacroGenics, Inc.
MGNX
$4.55 (3.65%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.